Several reports have shown that S-nitrosylation, the covalent binding of nitric oxide (NO) to reactive cysteine, plays an important role in the post-translational regulation of protein activity. S-nitrosylation is implicated in numerous physiological processes such as synaptic transmission, vasodilatation, angiogenesis and inflammatory response. The consequences of deficient or excessive S-nitrosylation are implicated in numerous diseases and especially in oncology and immunology. S-nitrosylation participates in cellular trafficking and cell signaling affecting cell motility, proliferation, differentiation and death. Therefore, S-nitrosylation plays important roles in cancerogenesis, tumor progression, tumor cell spreading as well as in lymphocyte development and autoimmune diseases.

S-nitrosylation is one of the main activities of NO and is dependent on both NO synthase activities and denitrosylase activities. The balance is probably regulated by the microenvironment. Therapeutic agents that are able to increase or decrease S-nitrosylation and already used in angina pectoris, could also be useful in cancer and immune diseases.

To make progress in the study of physiological and pathophysiological functions of S-nitrosylation and applications in therapeutics, there is an urgent need in the development of methods aimed at purifying and identifying SNO-proteins.

Participants
The conference is a forum for scientists, physicians, students, pharmaceutical companies and investigators in different disciplines: oncology, immunology, chemistry, biochemistry. Participants from all over the world are expected to attend this conference.